Citigroup’s Trillium Therapeutics Inc. TRIL Stock Holding History

Citigroup’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-36,104	Closed	-$634K	–	6249
2021 Q3	$634K	Buy	36,104 +30,448	+538%	+$356K	﹤0.01%	3448
2021 Q2	$55K	Buy	5,656 +4,656	+466%	+$43.8K	﹤0.01%	4779
2021 Q1	$11K	Hold	1,000	–	–	﹤0.01%	5612
2020 Q4	$15K	Buy	1,000 +300	+43%	+$4.33K	﹤0.01%	6813
2020 Q3	$10K	Sell	700 -400	-36%	-$3.99K	﹤0.01%	6661
2020 Q2	$9K	Buy	+1,100	New	+$6.8K	﹤0.01%	7117
2015 Q3	–	Sell	-52	Closed	-$1K	–	7884
2015 Q2	$1K	Buy	+52	New	+$1.19K	﹤0.01%	7380

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Citigroup's TRIL Position: Q4 2021 in Review

Citigroup sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 36,104 shares — an estimated $634K sold.

Citigroup first reported a position in TRIL in Q2 2015 and held it in 7 quarters. The position peaked at $634K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Citigroup reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Citigroup sold 36,104 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $634K.
Citigroup first reported a position in Trillium Therapeutics Inc. in Q2 2015 and held it in 7 quarters.
Citigroup's Trillium Therapeutics Inc. position peaked at $634K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Citigroup's 13F filing for Q4 2021, filed 10 Feb 2022.